logo
A 20-foot-long ‘mega raptor' once stalked Australia

A 20-foot-long ‘mega raptor' once stalked Australia

Yahoo19-02-2025

Modern Australia is known for its array of wildlife: poisonous snakes and spiders, saltwater crocodiles, koalas, kangaroos, and more. The continent was also once home to dinosaurs, including the giant Australotitan and flying pterosaur Haliskia petersensi.
Now, paleontologists have found remains of the world's oldest known megaraptorid–aka the 'mega raptor'–and the first evidence of a carcharodontosaurus in Australia. The fossils are described in a study published February 19 in the Journal of Vertebrate Paleontology and reveal what the predator hierarchy unique to Cretaceous Australia might have looked like.
The megaraptorids and carcharodontosaurus were theropod dinosaurs. Theopods were primarily carnivores and walked on two hind legs. They range in size from the small Coelurosaur up to the giant Tyrannosaurs. Several theropod species also had feathers.
The mega raptors belonged to a family of large-bodied dinosaurs from the Cretaceous Period (about 125 to 66 million years ago) called Megaraptoridae. They were about 20 feet long and have mostly been found in southern continents. Megaraptorids are known for somewhat small–but sharp–teeth, air-filled bones, and powerful forelimbs with enormous claws.
At roughly 45 feet-long, Carcharodontosaurus was among the largest land-dwelling carnivores in our planet's history. It also lived during the Cretaceous and has primarily been found in North Africa until now.
Paleontologists uncovered these five new theropod fossils along the coastline in the state of Victoria in southeastern Australia. They were unearthed in the upper Strzelecki Group (about 121.4 to 118 million years old) and the Eumeralla Formation (about 113 to 108 million years old). The fossils suggest that modern-Victoria's ancient ecosystem was dominated by these powerful theropods.
'The discovery of carcharodontosaurs in Australia is groundbreaking,' Jake Kotevski, a study co-author and Museums Victoria Research Institute and Monash University PhD student, said in a statement. 'It's fascinating to see how Victoria's predator hierarchy diverged from South America, where carcharodontosaurs reached Tyrannosaurus rex-like sizes up to 13 metres [42.6 feet], towering over megaraptorids. Here, the roles were reversed, highlighting the uniqueness of Australia's Cretaceous ecosystem.'
Two of the fossils represent the world's oldest known mega raptors and expand our understanding of the group's evolutionary history. Australia's theropod fauna could have played a pivotal role in the ecosystems of the ancient supercontinent Gondwana.
'The findings not only expand Australia's theropod fossil record but offer compelling evidence of faunal interchange between Australia and South America through Antarctica during the Early Cretaceous,' Thomas Rich, a senior curator of vertebrate palaeontology at Museums Victoria Research Institute and study co-author, said in a statement. 'The findings also challenge previous assumptions about body-size hierarchies in Gondwanan predator ecosystems highlighting Victoria's unique Cretaceous fauna.'
Three of the fossils were uncovered between 2022 and 2023 and were first identified by Museums Victoria volunteer Melissa Lowery. According to the team, this discovery highlights how volunteers and community members working alongside seasoned researchers can help uncover the secrets of Australia's Cretaceous past.
The team will also keep surveying these key fossil sites, including the spots where the large megaraptorid fossils were uncovered.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025

Business Upturn

time2 days ago

  • Business Upturn

Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025

Darmstadt, Germany: Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the primary endpoint of BICLA dose-response relationship at Week 24 was not met Data show encouraging efficacy in a large subgroup of SLE patients with active cutaneous manifestations at baseline, including improved response rates in key disease activity measurements There is a substantial unmet treatment need for the estimated 70-80% of SLE patients who experience active cutaneous manifestations, which can profoundly impact quality of life1 Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity in prespecified SLE subpopulations despite standard of care (SoC), including those with active cutaneous manifestations at baseline [(CLASI-A) ≥8], and was overall well tolerated. These findings will be presented in a late-breaking oral presentation at the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract # LB0004). 'Analyses of Cohort B contribute to our understanding of enpatoran's potential to address the critical unmet needs for patients living with lupus, including those experiencing significant skin manifestations. These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life,' said principal investigator Prof. Eric Morand, from Monash University and Monash Health. 'The improvements observed in key disease measures represent a meaningful advancement in our ongoing investigation of the TLR7/8 inhibition approach for patients insufficiently managed by current therapies.' WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of oral enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus SoC over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE). Cohort B of the study was designed to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at Week 24 and enrolled SLE patients who had moderate or severe active disease despite SoC. Cohort B showed positive results in secondary and exploratory endpoints and within prespecified patient subpopulations. In patients with active skin disease (CLASI-A ≥8), BICLA response rates were up to 58.6% while placebo response rates were 31.7%, and up to 60.5% of patients receiving enpatoran showed a CLASI-70 response, compared with 26.8% for placebo, at Week 24. In addition, the subgroups of patients with high corticosteroid (prednisone-equivalent ≥10 mg/day) use and those with high interferon gene signature (IFN-GS) at baseline also showed higher and relevant BICLA response rates for enpatoran compared to placebo. As presented earlier this year at LUPUS 2025, Cohort A analyses from the WILLOW study showed clinically meaningful improvement in disease activity in patients with CLE and mild SLE with active lupus rash at Weeks 16 and 24. Overall, for skin-related signs and symptoms, comparable improvements were observed in Cohort B relative to Cohort A, reinforcing the potential efficacy of enpatoran in patients with cutaneous manifestations of lupus erythematosus with or without systemic disease. 'The efficacy and tolerability results from Cohort B, including among those with active skin involvement—a manifestation that affects most lupus patients—are consistent with our observations from Cohort A. The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus,' said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck. 'We are set to initiate regulatory discussions with key health authorities to determine the most effective pathway for bringing enpatoran to patients.' Enpatoran was well-tolerated and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified. Rates of treatment-emergent adverse events (TEAEs) were comparable between all enpatoran arms and placebo, ranging from 60.6% to 64.2%, and the most frequently reported TEAEs were infections and infestations. These results further support the anticipated favorable safety profile of enpatoran. About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world. About the Phase 2 WILLOW Clinical Study WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment. About Lupus Erythematosus Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain, and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes, and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects. Merck in Neurology and Immunology Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG). About Merck Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service. 1 Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

New species of dinosaur discovered that 'rewrites' T.rex family tree
New species of dinosaur discovered that 'rewrites' T.rex family tree

Yahoo

time3 days ago

  • Yahoo

New species of dinosaur discovered that 'rewrites' T.rex family tree

Scientists have discovered a new species of dinosaur - in the collection of a Mongolian museum - that they say "rewrites" the evolutionary history of tyrannosaurs. Researchers concluded that two 86 million-year-old skeletons they studied belonged to a species that is now the closest known ancestor of all tyrannosaurs - the group of predators that includes the iconic The researchers named the species Khankhuuluu (pronounced khan-KOO-loo) mongoliensis, meaning Dragon Prince of Mongolia. The discovery, published in Nature, is a window into how tyrannosaurs evolved to become powerful predators that terrorised North America and Asia until the end of the reign of the dinosaurs. "'Prince' refers to this being an early, smaller tyrannosauroid," explained Prof Darla Zelenitsky, a palaeontologist from the University of Calgary in Canada. Tyrannosauroids are the superfamily of carnivorous dinosaurs that walked on two legs. The first tyrannosauroids though were tiny. PhD student Jared Voris, who led the research with Prof Zelenitsky, explained: "They were these really small, fleet-footed predators that lived in the shadows of other apex predatory dinosaurs." Khankhuuluu represents an evolutionary shift - from those small hunters that scampered around during the Jurassic period - to the formidable giants, including T-rex. It would have weighed about 750kg, while an adult could have weighed as much as eight times that, so "this is a transitional [fossil]," explained Prof Zelenitsky, "between earlier ancestors and the mighty tyrannosaurs". "It has helped us revise the tyrannosaur family tree and rewrite what we know about the evolution of tyrannosaurs," she added. The new species also shows early evolutionary stages of features that were key to the tyrannosaurs' tyranny, including skull anatomy that gave it a strong jaw. Jared Voris explained: "We see features in its nasal bone that eventually gave tyrannosaurs those very powerful bite forces." The evolution of such powerful jaws allowed T-rex to pounce on larger prey, and even bite through bone. Tyrannosaur's last meal was two baby dinosaurs Fossil reveals 240 million year-old 'dragon' Solving the mystery of a dinosaur mass grave The two partial skeletons that the team examined in this study were first discovered in Mongolia back in the early 1970s. They were initially assigned to an existing species, known as Alectrosaurus, but when Mr Voris examined them, he identified the Tyrannosaur-like features that set it apart. "I remember getting a text from him - that he thought this was a new species," recalled Prof Zelenitsky. The fact that this group of dinosaurs were able to move between North America and Asia - via land bridges that connected Siberia and Alaska at the time - also helped them to find and occupy different niches. Mr Voris explained: "That movement back and forth between the continents basically pushed the evolution of different tyrannosaur groups" over millions of years. Prof Zelinitsky added: "This discovery shows us that, before tyrannosaurs became the kings, they were they were princes."

‘The missing link': New early tyrannosaur species discovered by Calgary researchers
‘The missing link': New early tyrannosaur species discovered by Calgary researchers

Hamilton Spectator

time3 days ago

  • Hamilton Spectator

‘The missing link': New early tyrannosaur species discovered by Calgary researchers

CALGARY - Scientists from the University of Calgary have discovered a new dinosaur specimen that they say appears to be the 'missing link' in the evolution of tyrannosaurs. The specimen was originally discovered in Mongolia's Gobi Desert over 50 years ago in the 1970s. But its significance wasn't recognized until Darla Zelenitsky, an associate professor in the university's faculty of science, sent graduate student Jared Voris to Mongolia on a research trip. 'He was there a couple of years ago on this research trip and looked at the fossil and texted me (that) he thought it was a new species. I was like, 'yay,'' Zelenitsky told The Canadian Press. 'I said, 'This is good, but we don't want to jump the gun on this.' It turned out it (was) a new species.' The species, Khankhuuluu mongoliensis — meaning 'Dragon Prince' or 'Prince of Dragons of Mongolia' — is believed to have crossed via a land bridge from Siberia to Alaska roughly 85 million years ago. Zelenitsky said it appears to sit on the evolutionary scale between smaller tyrannosauroids and tyrannosaurs. 'It's the missing link between smaller tyrannosauroids and the large predatory tyrannosaurs,' she said. 'This missing link was around 750 kilograms. Its ancestors were a couple of hundred kilograms and just tiny, but then when you get to tyrannosaurs proper, they were over a thousand kilograms, up to estimates of 5,000 kilograms.' The findings were published Wednesday in the British weekly scientific journal 'Nature.' 'It's really exciting to be involved in a discovery of something that's been sitting in a drawer for 50 years. But it's even more exciting when it's a PhD student that makes that discovery,' Zelenitsky added. 'This discovery forced us to look at the family tree of tyrannosaurs in a very different light. It ended up with us rewriting the family history of tyrannosaurs.' The arrival of Khankhuuluu or a similar species after moving from Asia to North America may have been the result of following their prey to a new location, said Zelenitsky. 'It's possible that there weren't many tyrannosaur type predators so it's possible they were able to take over that niche in North America and moved to the top of the food chain,' she said. 'Tyrannosaurs were in the right place at the right time. It allowed them to diversity and evolve a large body size, ultimately becoming the massive apex predator that terrorized North America and Asia during the late Cretaceous period.' Zelenitsky said the evolution to the tyrannosaur happened rapidly, geologically speaking, and probably took a few million years. She has co-authored over 50 different publications during her career and was part of a team that first found evidence of feathered dinosaurs in North America. This report by The Canadian Press was first published June 11, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store